Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1918 1
1919 1
1920 1
1923 1
1932 1
1935 1
1950 1
1955 1
1972 1
1979 1
1980 1
1981 2
1982 1
1985 1
1987 3
1988 3
1989 3
1990 2
1991 3
1992 2
1993 2
1994 1
1995 2
1996 1
1997 1
1999 1
2000 1
2001 2
2008 1
2009 1
2011 1
2012 1
2013 1
2014 3
2015 3
2016 3
2017 2
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. Among authors: cameron gs. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Among authors: cameron gs. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO; Japanese Ixekizumab Study Group. Saeki H, et al. Among authors: cameron gs. J Dermatol. 2017 Apr;44(4):355-362. doi: 10.1111/1346-8138.13622. Epub 2016 Oct 11. J Dermatol. 2017. PMID: 27726163 Free PMC article. Clinical Trial.
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM. Papp KA, et al. Among authors: cameron gs. Br J Dermatol. 2018 Mar;178(3):674-681. doi: 10.1111/bjd.16050. Epub 2018 Feb 23. Br J Dermatol. 2018. PMID: 28991370 Clinical Trial.
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. Krueger JG, et al. Among authors: cameron gs. J Allergy Clin Immunol. 2012 Jul;130(1):145-54.e9. doi: 10.1016/j.jaci.2012.04.024. Epub 2012 Jun 5. J Allergy Clin Immunol. 2012. PMID: 22677045 Free PMC article. Clinical Trial.
Paediatric outpatient surgery under general anaesthesia.
Rigg JR, Dunn GL, Cameron GS. Rigg JR, et al. Among authors: cameron gs. Anaesth Intensive Care. 1980 Nov;8(4):451-3. doi: 10.1177/0310057X8000800411. Anaesth Intensive Care. 1980. PMID: 7457816
Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
Imafuku S, Torisu-Itakura H, Nishikawa A, Zhao F, Cameron GS; Japanese UNCOVER-1 Study Group. Imafuku S, et al. Among authors: cameron gs. J Dermatol. 2017 Nov;44(11):1285-1290. doi: 10.1111/1346-8138.13927. Epub 2017 Jun 21. J Dermatol. 2017. PMID: 28635026 Free PMC article. Clinical Trial.
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. Edson-Heredia E, et al. Among authors: cameron gs. J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5. doi: 10.1111/jdv.13032. Epub 2015 Mar 13. J Eur Acad Dermatol Venereol. 2016. PMID: 25773781 Clinical Trial. No abstract available.
Modulation of blood pressure by central melanocortinergic pathways.
Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Greenfield JR, et al. Among authors: cameron gs. N Engl J Med. 2009 Jan 1;360(1):44-52. doi: 10.1056/NEJMoa0803085. Epub 2008 Dec 17. N Engl J Med. 2009. PMID: 19092146 Free article.
56 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page